Category: Treatment


Melanoma Mortality Rate Continues Decline Fueled by Treatment Advances

By Cody Barnett, MPH, MRA Director of Communications & Patient Engagement | 26 January 2022 In News, Prevention, Science, Treatment

Each January, the American Cancer Society (ACS) releases updated estimates about trends in new cancer cases and deaths in its annual report, Cancer Facts and Figures. This report highlights the estimated incidence (number of new cases), prevalence (number of people alive today with a history of cancer), and survival statistics for cancer in the United States.

Read More


MRA Celebrates Approval of Tebentafusp - First Drug for Metastatic Uveal Melanoma

By Cody Barnett, MPH, MRA Director of Communications & Patient Engagement | 26 January 2022 In News, Treatment

The Melanoma Research Alliance (MRA), the largest non-profit funder of melanoma research worldwide, applauds the U.S. Food and Drug Administration (FDA) decision to approve the first-ever therapy for metastatic or unresectable uveal melanoma.

Read More


Registration Now Open for March 9 Patient Forum!

11 January 2022 In Allies & Partnerships, Events, News, Policy, Prevention, Science, Treatment

MRA’s Melanoma Exchange Patient Forum, held in-person in Washington DC and virtually on March 9, will bring together melanoma patients, survivors, advocates, and their loved ones to provide lay-friendly, state-of-the-science education, promote collaboration, and provide networking opportunities across the melanoma community.

Read More


Championing Clinical Trials

By Cody Barnett, MPH, MRA Director of Communications & Patient Engagement | 2 January 2022 In Melanoma Stories, Science, Treatment

Too often, the first time someone is exposed to clinical trials is when they've been diagnosed with a serious, life threatening illness. Learn how Mary Elizabeth partnered with her doctor Jedd Wolchok to take back control from melanoma.

Read More


MRA Applauds Expanded Approval of Pembrolizumab to Patients with Stage 2 Melanoma

By Cody Barnett, MPH, MRA Director of Communications & Patient Engagement | 6 December 2021 In News, Science, Treatment

The Melanoma Research Alliance (MRA), the largest non-profit funder of melanoma research worldwide, welcomes the U.S. Food and Drug Administration (FDA) decision to expand eligibility of Merck’s Keytruda (pembrolizumab) to include patients with Stage IIB and IIC melanoma.

Read More


Promising Uveal Melanoma Research Advances

By Cody Barnett, MPH, MRA Director of Communications & Patient Engagement | 26 October 2021 In News, Science, Treatment

Uveal melanoma, often called ocular melanoma or just eye melanoma, is a rare melanoma subtype that affects about 2,500 people each year in the United States. As is true with other rare subtypes, we know far less about what causes uveal melanoma, how it progresses, and how it can be...

Read More


Challenge Accepted: MRA 2020 - 2021 Annual Report

19 October 2021 In Allies & Partnerships, Melanoma Stories, News, Policy, Prevention, Science, Treatment

This was a year like no other. COVID-19 presented new challenges that required new ways of thinking. At MRA, confronting challenges is part of our DNA. We never stop challenging ourselves, no matter the odds or obstacles, in pursuit of conquering melanoma and saving lives.

Read More


The Next Frontier of Combination Immunotherapy: Maximizing the Benefits & Reducing Harms

15 September 2021 In Science, Treatment

Every general knows that the best way to successfully win a war is to deploy multiple weapons with different targets. This strategy was first used in cancer to conquer childhood leukemias with combination chemotherapy and now is being put to the test in melanoma by combining multiple checkpoint inhibitors, as...

Read More


Practical Recommendations for Surviving and Thriving Despite Melanoma

4 August 2021 In Treatment

Most experts, including the National Cancer Institute, say that a person becomes a survivor from the moment they learn of their cancer diagnosis – for the rest of their life. Get practical tips and strategies to live well with melanoma based on an expert panel conversation, led by Dr. Sapna Patel of the University of Texas M.D. Anderson Cancer Center.

Read More


Full Sails Ahead: Immunotherapy Shows Continued Survival Benefit for Patients Facing Advanced Melanoma

By Cody Barnett, MPH, MRA Director of Communications & Patient Engagement | 28 July 2021 In News, Science, Treatment

After carefully following patients enrolled in Checkmate 067 over the last 6.5 years, he and the research team determined that 49% of patients treated with Opdivo + Yervoy were alive at 6.5 years and 77% of these patients remained treatment-free. This represents the longest reported median overall survival in a phase 3 melanoma clinical trial – ever.

Read More


Login

×